Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 3/20 | 0.71 |
| ▸ | BRAF | P15056 | 11/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933572 | 0.91 | PIM3 (0.63) | PIM3BRAFRAF1CHEK1MAPK8 | |
| SCHEMBL2932403 | 0.85 | PIM3 (0.53) | PIM3BRAFRAF1CHEK1PIK3CG | |
| SCHEMBL13515311 | 0.83 | PIM3 (0.54) | PIM3BRAFRAF1CHEK1HPGD | |
| SCHEMBL2934370 | 0.83 | PIM3 (0.51) | PIM3BRAFRAF1CHEK1 | |
| SCHEMBL14269639 | 0.83 | PIM3 (0.55) | PIM3BRAFRAF1 | |
| SCHEMBL2935985 | 0.82 | PIM3 (0.58) | PIM3CSNK2A1HPGD | |
| SCHEMBL13515278 | 0.81 | FYN (0.59) | PIM3BRAFRAF1CHEK1HPGD | |
| SCHEMBL13515297 | 0.81 | PIM3 (0.54) | PIM3BRAFRAF1 | |
| SCHEMBL2927502 | 0.81 | PIM3 (0.51) | PIM3BRAFRAF1CHEK1 | |
| Trifluoroacetic Acid SCHEMBL2933929 | 0.81 | PIM3 (0.51) | PIM3BRAFRAF1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | PIM3 2131/4885BRAF 524/4885RAF1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.